Experience of patients with diffuse large B-cell lymphoma participating in clinical trials of CAR-T cell therapy: a qualitative study
10.3760/cma.j.cn115682-20250217-00684
- VernacularTitle:弥漫大B细胞淋巴瘤患者参与CAR-T细胞疗法临床试验体验的质性研究
- Author:
Ximei TIAN
1
;
Chuqiao WU
;
Xinfeng CHEN
;
Weiling SHI
Author Information
1. 郑州大学第一附属医院生物免疫治疗病区/生物细胞治疗中心，郑州 450000
- Publication Type:Journal Article
- Keywords:
Lymphoma;
Chimeric antigen receptor T cell immunotherapy;
Clinical trial;
Experience
- From:
Chinese Journal of Modern Nursing
2025;31(24):3280-3285
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the real experience of patients with diffuse large B-cell lymphoma in clinical trials of chimeric antigen receptor T (CAR-T) cell therapy, providing reference for clinical practice.Methods:This study was descriptive qualitative research. From January to December 2024, 15 patients with diffuse large B-cell lymphoma who completed a clinical trial of CAR-T cell therapy in Ward of Biological Immunotherapy of the First Affiliated Hospital of Zhengzhou University were selected by purposive sampling method for semi-structured interviews. The data was analyzed by content analysis method.Results:The experience of patients with diffuse large B-cell lymphoma participating in the clinical trial of CAR-T cell therapy were summarized into three themes and 12 sub-themes, namely, the pre-enrollment situation and attitude towards the clinical trial: survival from adversity (caught in the dilemma of treatment, grasping the last hope, survival desire overcoming fear, active psychological construction), social support and power source in the clinical trial: support network (unnoticeable personal strength, multi-dimensional family support system, professional medical support system, weak peer support system), and experience and feeling after CAR-T cell therapy: positive experience driven by efficacy (satisfaction with treatment effectiveness and clinical trials, pleased with reduced adverse reactions, increased confidence in treating diseases, adverse reactions were not scary) .Conclusions:Patients with diffuse large B-cell lymphoma have an overall positive experience during clinical trials of CAR-T cell therapy, but the negatives should not be ignored. Healthcare professionals should strengthen the health education of clinical trials, assist patients to improve the social support network, make up for the short board of patient support, alleviate the adverse reactions of patients, and then increase the enthusiasm of patients to participate in clinical trials.
